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In patients with multiple myeloma (MM) extramedullary (EM) lesions could be a possible indicator of poor prognosis. 
Twist 1, an EMT related transcription factor, is known to play an important role in embryonic development and also in the 
process of tumor cell proliferation, apoptosis, metastasis etc. The Twist 1 protein expression hence has prognostic 
significance in MM. This study investigates expression of Twist-1 in MM patients with extramedullary lesions and its 
relationship with clinicopathological data and prognosis, so as to elucidate the clinical significance of Twist-1 expression. 
Patients with MM complicated with EM lesions were selected retrospectively, including 35 cases in the bone marrow group 
(MM complicated with extramedullary lesions) and 80 cases in the extramedullary group (MM combined with 
extramedullary lesions). The expression of Twist 1 protein was detected by immunohistochemistry. The relationship 
between Twist 1 protein expression and general clinicopathological data was analyzed by statistics. The relationship 
between Twist 1 protein expression and prognosis was analyzed by COX single factor and multivariate regression analysis. 
Immunohistochemical staining showed that the expression level of Twist-1 protein in the nucleus of myeloma cells in the 
extramedullary group was significantly higher than that of the bone marrow group. However, in the cytoplasm of myeloma 
cells, there was no significant difference in the expression level of Twist-1 protein between the extramedullary group and 
the bone marrow group. The expression level of Twist-1 protein in extramedullary tissue was not related to sex, age, D-S 
stage, ISS stage, immunoglobulin type, creatinine and hemoglobin. The expression level of β2-microglobulin in Twist-1 
high expression group was significantly higher than that of Twist-1 low expression group. Follow-up findings discovered 
that overall survival (OS) of Twist 1 high expression group was significantly lower than that of Twist 1 low expression 
group. COX multivariate analysis showed that Twist 1 protein and International Staging System (ISS) stage were 
independent risk factors affecting OS for 3 years. The high expression rate of Twist 1 protein in extramedullary lesions of 
MM patients with extramedullary lesions is significantly higher than that in bone marrow tissues of patients with 
extramedullary lesions. The results suggest that high expression of Twist 1 protein is an independent risk factor affecting the 
prognosis of MM patients with extramedullary lesions.  
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Myeloma is a malignant proliferative disease originating 
from plasma cells. With the main clinical performances 
of clonal proliferation of plasma cells and massive 
secretion of monoclonal immunoglobulin, it is a 
common malignant disease in the hematology 
department. Multiple myeloma (MM) is the most 
common type of myeloma, ranking the second among 
malignant diseases of the blood system with an 
incidence rate of 13%2. Extramedullary lesions are the 
most common way for myeloma to metastasize when 
the lesions protrude from damaged bone sites. 
Extramedullary lesions cannot affect a radical cure with 
the characteristics of strong atypia and tumor cells and 
the low differentiated degree3, which pose a heavy 
impact on patients and families. Hence, it becomes 
necessary to explore MM with extramedullary lesions 
for effective treatment. Studies have confirmed that 
Epithelial mesenchymal transformation (EMT), as the 
basis of embryonic development, is involved in a variety 
of biological processes, such as loss of cell-cell 
adhesion, tumor infiltration, tumor migration, etc.4.  
Twist 1 is an EMT related transcription factor that 
not only plays an important role in embryonic 
development, but also participates in the process of 
tumor cell proliferation, apoptosis, epithelial interstitial 
transformation, metastasis and neovascularization5. High 
expression of Twist 1 protein was found in some 
malignant tumors, such as lung cancer, liver cancer and 
prostate cancer, and its expression is reported to 
be closely related to poor prognosis6. Until now, 
the expression of Twist 1 protein in MM with 
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extramedullary diseases and its prognostic significance 
have been rarely reported. In this context, here, we 
examined the expression of Twist 1 in bone marrow and 
extramedullary lesions of patients with MM and 
extramedullary lesions and analyzed their relationship 
with prognosis in order to provide more basis for the 
treatment of clinical myeloma. 
 
Materials and Methods  
 
General clinical data  
From May 2011 to May 2018, 80 patients with 
MM complicated with extramedullary lesions were 
selected retrospectively, including 45 male cases and 
35 female cases at an average age of 11-16 years 
(4~18). There were 16 cases with IgA, 47 cases  
with IgG, 7 cases with IgD, 4 cases with no secretion 
and 6 cases with light chain. All patients received 
bortezomib or thalidomide chemotherapy. The 
patients were all newly diagnosed without regular 
radiotherapy or any previous chemotherapy. Patients 
with other malignant diseases, osteoporosis, and 
serious infectious diseases were excluded. A total of 
20 healthy bone marrow donors with matching sex 
and age were selected as control group. The subjects 
had complete clinical data. This study was approved 
by the hospital ethics committee and informed 
consent was signed by the subjects and their families. 
The specimens were fixed and embedded with 4% 
paraformaldehyde. The follow-up period starts from 
surgical removal of diseased tissue to December 1, 
with 20 deaths during the period. This study was 
approved by the Institutional Ethical Committee for 
Medical Research with necessary informed consents 
from the participating subjects. 
 
Main instruments and reagents  
Paraffin slicing machine (purchased from Germany 
Leica Company), optical microscope (purchased  
from Japan Olympus Corporation), Citrate antigen  
repair solution, DAB Chromogenic kit, SP 
Immunohistochemical kit, hematoxylin-eosin stain 




The bone marrow tissues and extramedullary tissues 
treated with 4% neutral formaldehyde solution fixation, 
paraffin embedding, and 4 μm thickness sections, and 
were placed on pre-treated slides with 10% poly-lysine 
solution and dried before baking. The tissues were 
placed at 4 for standby use after reducing to the room 
temperature. The immunohistochemical staining was 
carried out according to the instructions of DAB 
chromogenic kit and SP immunohistochemical kit. PBS 
was used as the negative control instead of the primary 
antibody. The staining results were determined by two 
experienced pathologists. A comprehensive assessment 
of the percentage of positive cells and the extent of 
staining was carried out, and the colour depth score 
criteria were obtained: 0 (no colour), 1 (light yellow),  
2 (brownish yellow), 3 (dark brown); Criteria  
for percentage of positive cells: 0 (no expression),  
1 (1~25%), 2 (26~50%), 3 (51~75%), 4 (>75%) The 
scores were divided into high expression group (4~12) 
and low expression group (0~3).  
 
Statistical methods  
SPSS21.0 statistical software package was used for 
data analysis. The measurement data consistent with 
normal distribution were all expressed in the mean ± 
standard deviation. Twist 1 high expression rate and 
other enumeration data were expressed in [n(%)]. χ² test 
or t test was taken for inter-group differences. Non-
normal distribution data are expressed as median values. 
U test was carried out for the difference between two.  
A Pearson correlation analysis method was used to 
analyze protein expression correlation. The survival 
curve was drawn by Kaplan-Meier method and Logrank 
test was used to compare the single-factor survival rate. 
COX proportional hazards regression model was used 
for the multivariate analysis, such as age, sex, etc.  
A value of P <0.05 was considered statistically 




Expression of Twist 1 in tissues of extramedullary group and 
bone marrow group  
Immunohistochemical staining showed that the 
expression level of Twist-1 protein in the nucleus of 
myeloma cells in the extramedullary group was 
significantly higher than that in the bone marrow 
group and the difference was statistically significant 
(P <0.05); in the cytoplasm of myeloma cells, there 
was no significant difference in the expression level 
of Twist-1 protein between the extramedullary group 
and the bone marrow group (P >0.05) (Fig. 1 and 
Table 1).  
 
Relationship between Twist 1 protein expression level and 
clinicopathological types in extramedullary group tissues  
The expression level of Twist-1 protein in 
extramedullary tissue was not related to sex, age, D-S 
stage, ISS stage, immunoglobulin type, creatinine  
and hemoglobin. The expression level of β2-




microglobulin in Twist-1 high expression group was 
significantly higher than that in Twist-1 low 
expression group and the difference was statistically 
significant (P <0.05) (Table 2). 
 
Effect of high expression of twist 1 protein on prognosis  
Follow-up findings discovered that the three-year 
overall survival rate (OS) (55.00%) of patients in high 
protein expression group Twist 1 was obviously lower 
than that in Twist 1 low expression group (85.00%) 
and the difference was statistically significant  
(P <0.05) (Fig. 2). 
 
Relationship between high expression of Twist 1 protein and 
prognosis analyzed with COX single factor and multiple 
factors  
Univariate analysis found that DS staging, ISS 
staging, β2- microglobulin, Twist 1 protein were all 
related to the patient's 3-year OS. Multivariate 
analysis showed that Twist 1 protein and ISS staging 
were independent risk factors affecting 3-year OS  
(P <0.05) (Table 3).  
 
Discussion  
Multiple myeloma (MM) is one of the most common 
malignant tumors in the blood system, characterized by 
clonal proliferation of plasma cells and the secretion of 
many monoclonal immunoglobulin. Patients are prone 
to extramedullary infiltration, extensive late metastasis, 
and poor prognosis. With no radical curve method, MM 
becomes a major disease threatening the health and 
safety of patients7. Radiotherapy and chemotherapy are 
commonly used in clinical treatment, but the individual 
sensitivity of drugs varies greatly, and the 5-year 
survival rate has not been greatly improved8. Therefore, 
it is of great significance for MM patients to study the 
molecular mechanism of MM etiology and to seek a 
new direction of new targeted drugs for MM therapy.  
This study found that the high expression rate  
of Twist 1 protein in the nucleus of tumor cells in  
MM patients with extramedullary infiltration was 
significantly higher than that in their bone marrow 
tissue. Multivariate risk regression analysis showed that 
high expression of Twist 1 protein in extramedullary 
tissue was an independent risk factor for short PFS and 
 
 
Fig. 1 — Immunohistochemical staining of Twist 1 in (A) Bone 
marrow group; and (B) Extramedullary group 
 
Table 1 — Expression of Twist 1 in tissues of extramedullary 
group and bone marrow group 
Group No. 





Bone marrow group  35 3 (8.6) 14 (40.0) 
Extramedullary group  80 20 (25.0) 43 (53.8) 
χ²   4.107 1.841 
P   0.043 0.175 
 
Table 2 — Relationship between Twist 1 protein expression level 
and clinicopathological types in extramedullary group tissues 
Parameter  Twist 1 low 
expression  
Twist 1 high 
expression  
P  
 N＝60 N＝20  
Age  12 (4~18) 15 (7~16) 0.420 
Male  34 11 0.799 
Duie-Salmon (DS) staging    0.201 
Ⅰ 15 2  
Ⅱ 21 7  
Ⅲ 24 11  
International Staging System 
(ISS) staging  
  0.061 
Ⅰ 12 2  
Ⅱ 25 5  
Ⅲ 23 13  
Immunoglobulin class    0.129 
IgA  12 3  
IgG  33 8  
IgD 3 4  
No secretion type  4 0  
Light chain type  8 5  
Creatinine (μmol/L)    0.430 
>176.8  4 3  
<176.8  56 17  






β2-microglobulin (μg/mL)  4.32 (1.12-
12.21) 




Fig. 2 — Curve diagram of Twist 1 high protein expression to 3-
year survival rate 
 




OS in patients. The results of the present study provide a 
useful reference for evaluating the prognosis of patients 
with MM and extramedullary infiltration.  
Twist 1 is a conservative transcription factor in 
evolution, belonging to the basic helix-loop-helix 
protein family9. Existing studies suggest that Twist 1 
not only plays an important role in embryonic 
development, but also participates in the proliferation, 
apoptosis, epithelial interstitial transformation, 
metastasis, neovascularization and other processes of 
tumor cells. High expression of Twist 1 protein was 
found in some malignant tumors, such as lung cancer, 
liver cancer and prostate cancer, and its expression 
was closely related to poor prognosis10. During the 
progression of cancer cells, through strengthening 
nucleosome remodeling and recruitment of 
deacetylase complex, Twist 1 can directly inhibit E-
cadherin expression, cause epithelial mesenchymal 
transformation, and then promote tumor metastasis11. 
In patients with some mesenchymal tumors such as 
osteosarcoma, both progression-free survival and 
overall survival rates are low and closely related to 
metastasis in patients with high Twist 1 expression. 
There is a high expression of Twist 1 in melanoma 
cells. Compared with the primary site, the expression 
level Twist 1 of the metastatic site is higher12. Some 
scholars have established Twist 1 protein stable 
expressions with virus vector and found that the up-
regulation of Twist 1 protein can induce stem cell-like 
changes in cells, and tumor blood vessels and tumor 
globular changes can be found in cell mass. In the 
process of participating in EMT as embryonic 
development genes, anomalous expression of Twist 1 
protein in breast cancer and prostate cancer was 
confirmed13. With regard to diseases of the blood 
system, high expression of Twist 1 protein was found 
in leukemic cells such as acute myeloid leukemia and 
its proliferation ability was enhanced and apoptosis 
was inhibited14. With regard to MM, under hypoxic 
conditions, EMT protein may be activated, which can 
reduce the expression of E-cadherin protein and 
promote the infiltration and metastasis of myeloma 
cells15. Twist 1 is an important transcription factor to 
maintain the basic characteristics of the mesophyll of 
tumor and synovial sarcoma. The current study has 
shown that 3-year overall survival (OS) of Twist 1 
high expression group was significantly lower than 
that of the low expression group (P <0.05). This 
suggests that Twist 1 is not only an important 
participant in the development of epithelial tumors, 
but also plays an important role in the progression of 




Twist 1 protein is mainly expressed in the tumor 
nucleus of Multiple myeloma (MM) patients. It is 
highly expressed in bone marrow lesion tissue and 
extramedullary lesion tissue, and the high expression 
rate of Twist 1 protein in extramedullary lesion tissue 
is significantly higher than that in bone marrow tissue. 
High expression of Twist 1 protein is an independent 
risk factor for prognosis of MM patients with 
extramedullary lesions. A subgroup analysis is not 
possible to further describe the process in terms of 
EMT and tumor angiogenesis due to limited sample 
size and lack of molecular biology and genetics data. 
Much information and samples are still needed to 
clarify the specific mechanism of Twist 1 and MM.  
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